SLC25A25-AS1 downregulation was found to dramatically potentiate CRC proliferation, EMT and 5-FU resistance by activating the MAPK/ERK signalling pathway through Erk and p38. This evidence concerns the gene SLC25A25 and colorectal carcinoma.